Research Progress on The Mechanism and Treatment of Inflammatory Response in Myocardial Ischemia-Reperfusion Injury
Keywords:Acute myocardial infarction, myocardial ischemia-reperfusion injury, NLR, caspase, interleukin
Acute myocardial infarction can be treated aggressively with intravenous thrombolysis, percutaneous coronary intervention, and coronary artery bypass grafting; however, recanalization can cause myocardial ischemia-reperfusion injury (MIRI). This is an important reason that restricts the treatment effect of patients. After the ischemic myocardium is restored to perfusion, an inflammatory response can occur within minutes and peak within a few days. Many pro-inflammatory cytokines can seriously damage cardiac function. Inflammation can regulate cardiomyocyte apoptosis, autophagy, pyroptosis, and necrosis, and is the main initiating factor leading to MIRI in cardiomyocytes.
This article reviews the mechanism of inflammatory response in the ischemia-reperfusion period after acute myocardial infarction and the clinical value and application prospect of inhibiting inflammatory response in the treatment of acute myocardial infarction.
Audia JP, Yang XM, Crockett ES, et al. 2018. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function[J]. Basic Res Cardiol. 113(5):32.
Babamale AO, Chen ST. 2021. Nod-like Receptors: Critical Intracellular Sensors for Host Protection and Cell Death in Microbial and Parasitic Infections[J]. Int J Mol Sci. 22(21).
Chen L, Liu P, Feng X, et al. 2017. Salidroside suppressing LPS-induced myocardial injury by inhibiting ROS-mediated PI3K/Akt/mTOR pathway in vitro and in vivo[J]. J Cell Mol Med. 21(12):3178-3189.
Dabouz R, Cheng CWH, Abram P, et al. 2020. An allosteric interleukin-1 receptor modulator mitigates inflammation and photoreceptor toxicity in a model of retinal degeneration[J]. Journal of Neuroinflammation. 17(1).
Davidson SM, Ferdinandy P, Andreadou I, et al. 2019. Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury[J]. Journal of the American College of Cardiology. 73(1):89-99.
de Dios C, Bartolessis I, Roca-Agujetas V, et al. 2019. Oxidative inactivation of amyloid beta-degrading proteases by cholesterol-enhanced mitochondrial stress[J]. Redox Biol. 26:101283.
DeFilippis AP, Chapman AR, Mills NL, et al. 2019. Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury[J]. Circulation. 140(20):1661-1678.
Do CH, Arjun S, Petrucci O, et al. 2018. The Caspase 1 Inhibitor VX-765 Protects the Isolated Rat Heart via the RISK Pathway[J]. Cardiovasc Drugs Ther. 32(2):165-168.
Fan Q, Tao R, Zhang H, et al. 2019. Dectin-1 Contributes to Myocardial Ischemia/Reperfusion Injury by Regulating Macrophage Polarization and Neutrophil Infiltration[J]. Circulation. 139(5):663-678.
Fearon WF, Fearon DT. 2008. Inflammation and Cardiovascular Disease[J]. Circulation. 117(20):2577-2579.
Frati G, Schirone L, Chimenti I, et al. 2017. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy[J]. Cardiovasc Res. 113(4):378-388.
Huang XW, Pan MD, Du PH, et al. 2018. Arginase-2 protects myocardial ischemia-reperfusion injury via NF-kappaB/TNF-alpha pathway[J]. Eur Rev Med Pharmacol Sci. 22(19):6529-6537.
Jacotot É. 2020. Inhibition des caspases[J]. médecine/sciences. 36(12):1143-1154.
Jia X, Yan R, Lin H, et al. 2022. TBBPA and its alternative TCBPA induced ROS-dependent mitochondria-mediated apoptosis in the liver of Rana nigromaculata[J]. Environ Pollut. 297:118791.
Kleveland O, Kunszt G, Bratlie M, et al. 2016. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial[J]. Eur Heart J. 37(30):2406-2413.
Lafuse WP, Wozniak DJ, Rajaram M. 2020. Role of Cardiac Macrophages on Cardiac Inflammation, Fibrosis and Tissue Repair[J]. Cells. 10(1).
Li D, Yang S, Xing Y, et al. 2021. Novel Insights and Current Evidence for Mechanisms of Atherosclerosis: Mitochondrial Dynamics as a Potential Therapeutic Target[J]. Front Cell Dev Biol. 9:673839.
Li X, Yao X, Zhu Y, et al. 2019. The Caspase Inhibitor Z-VAD-FMK Alleviates Endotoxic Shock via Inducing Macrophages Necroptosis and Promoting MDSCs-Mediated Inhibition of Macrophages Activation[J]. Frontiers in Immunology. 10.
Liang H, Sun Y, Gao A, et al. 2019. Ac-YVAD-cmk improves neurological function by inhibiting caspase-1-mediated inflammatory response in the intracerebral hemorrhage of rats[J]. Int Immunopharmacol. 75:105771.
Lu QY, Ma JQ, Duan YY, et al. 2019. Carthamin Yellow Protects the Heart Against Ischemia/Reperfusion Injury With Reduced Reactive Oxygen Species Release and Inflammatory Response[J]. J Cardiovasc Pharmacol. 74(3):228-234.
Ma Z, Li K, Chen P, et al. 2020. Propofol Attenuates Inflammatory Damage via Inhibiting NLRP1-Casp1-Casp6 Signaling in Ischemic Brain Injury[J]. Biological & pharmaceutical bulletin. 43(10):1481-1489.
Mastrocola R, Penna C, Tullio F, et al. 2016. Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways[J]. Oxidative Medicine and Cellular Longevity. 2016:1-11.
McKernan DP. 2020. Pattern recognition receptors as potential drug targets in inflammatory disorders[J]. Advances in protein chemistry and structural biology. 119:65-109.
Mocanu MM, Baxter GF, Yellon DM. 2000. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury[J]. Br J Pharmacol. 130(2):197-200.
Monnier PP, D'Onofrio PM, Magharious M, et al. 2011. Involvement of caspase-6 and caspase-8 in neuronal apoptosis and the regenerative failure of injured retinal ganglion cells[M].
Munjal A, Khandia R. 2020. Atherosclerosis: orchestrating cells and biomolecules involved in its activation and inhibition[J]. Adv Protein Chem Struct Biol. 120:85-122.
Nagyőszi P, Nyúl-Tóth Á, Fazakas C, et al. 2015. Regulation of NOD-like receptors and inflammasome activation in cerebral endothelial cells[J]. Journal of Neurochemistry. 135(3):551-564.
Perrin C, Ecarnot-Laubriet A, Vergely C, et al. 2003. Calpain and caspase-3 inhibitors reduce infarct size and post-ischemic apoptosis in rat heart without modifying contractile recovery[J]. Cell Mol Biol (Noisy-le-grand). 49 Online Pub:L497-L505.
Pluijmert NJ, Bart CI, Bax WH, et al. 2020. Effects on cardiac function, remodeling and inflammation following myocardial ischemia-reperfusion injury or unreperfused myocardial infarction in hypercholesterolemic APOE*3-Leiden mice[J]. Sci Rep. 10(1):16601.
Qin Q, Liu H, Shou J, et al. 2021. The inhibitor effect of RKIP on inflammasome activation and inflammasome-dependent diseases[J]. Cell Mol Immunol. 18(4):992-1004.
Rudolphi K, Gerwin N, Verzijl N, et al. 2003. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis[J]. Osteoarthritis Cartilage. 11(10):738-746.
Shah PK, Lecis D. 2019. Inflammation in atherosclerotic cardiovascular disease [version 1; peer review: 4 approved][J]. F1000 research. 8:1402.
Tan Y, Mui D, Toan S, et al. 2020. SERCA Overexpression Improves Mitochondrial Quality Control and Attenuates Cardiac Microvascular Ischemia-Reperfusion Injury[J]. Mol Ther Nucleic Acids. 22:696-707.
Tenthorey JL, Haloupek N, Lopez-Blanco JR, et al. 2017. The structural basis of flagellin detection by NAIP5: A strategy to limit pathogen immune evasion[J]. Science. 358(6365):888-893.
van Hout GPJ, Bosch L, Ellenbroek GHJM, et al. 2016. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction[J]. European Heart Journal. w247.
Wang D, Lv L, Xu Y, et al. 2021. Cardioprotection of Panax Notoginseng saponins against acute myocardial infarction and heart failure through inducing autophagy[J]. Biomed Pharmacother. 136:111287.
Wang J, Zhou H. 2020. Mitochondrial quality control mechanisms as molecular targets in cardiac ischemia–reperfusion injury[J]. Acta Pharmaceutica Sinica B. 10(10):1866-1879.
Zhang J, Huang L, Shi X, et al. 2020. Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway[J]. Aging (Albany NY). 12(23):24270-24287.
Zhou H, Ren J, Toan S, et al. 2021. Role of mitochondrial quality surveillance in myocardial infarction: From bench to bedside[J]. Ageing Res Rev. 66:101250.
Zhu H, Tan Y, Du W, et al. 2021. Phosphoglycerate mutase 5 exacerbates cardiac ischemia-reperfusion injury through disrupting mitochondrial quality control[J]. Redox Biol. 38:101777.
Zhu H, Toan S, Mui D, et al. 2021. Mitochondrial quality surveillance as a therapeutic target in myocardial infarction[J]. Acta Physiol (Oxf). 231(3):e13590.
Zhu J, Huang J, Dai D, et al. 2019. Recombinant human interleukin-1 receptor antagonist treatment protects rats from myocardial ischemia–reperfusion injury[J]. Biomedicine & Pharmacotherapy. 111:1-5.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).